897396-10-0

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
9-Benzyl-3,9-diaza-bicyclo[4.2.1]nonan-4-one is used as a precursor in the synthesis of biologically active molecules for various pharmaceutical applications. Its unique structure and functional groups contribute to the development of neuropeptide Y receptor antagonists and somatostatin receptor ligands, which have potential therapeutic uses in treating various diseases and conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 9-Benzyl-3,9-diaza-bicyclo[4.2.1]nonan-4-one is utilized as a versatile building block for the synthesis of complex organic molecules. Its chemical properties and synthetic versatility make it an essential component in the design and development of new drugs and pharmaceutical agents.
Used in Organic Synthesis:
9-Benzyl-3,9-diaza-bicyclo[4.2.1]nonan-4-one is employed as a key intermediate in organic synthesis, allowing chemists to create a wide range of complex organic compounds. Its unique bicyclic structure and functional groups provide a solid foundation for the development of novel organic molecules with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

Upstream product

• 28957-72-4 N-benzyltropinone 
• 100-46-9 benzylamine 
• 542-05-2 acetonedicarboxylic acid 

Downstream Products

• 1059700-88-7 8-cyclohexyl-N-(N,N-dimethylsulfamoyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,9-diazabicyclo[4.2.1]nonane-9-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide trifluoroacetate 
• 1272321-67-1 13-benzyl-3-chloro-6,7,8,9,10,11-hexahydro-7,10-epiminobenzo[4,5]imidazo[1,2-a]azocine 
• 653600-90-9 (+/-)-9-benzyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylic acid tert-butyl ester 
• 387870-06-6 (+/-)-1-(9-benzyl-3,9-diazabicyclo[4.2.1]non-3-yl)ethanone 
• 286947-16-8 3-tert-butoxycarbonyl-3,9-diazabicyclo-[4.2.1]-nonane 
• 387870-07-7 (+/-)-1-(3,9-diazabicyclo[4.2.1]non-3-yl)ethanone 
• 108437-46-3 (+/-)-9-benzyl-3,9-diazabicyclo[4.2.1]nonane 

Relevant academic research and scientific papers

Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

New ligands with affinity for the α4β2 subtype of nicotinic acetylcholine receptors. Synthesis, receptor binding, and 3D-QSAR modeling

A new series of piperazines, diazepanes, diazocanes, diazabicyclononanes, and diazabicyclodecanes with affinity for the α4β 2 subtype of nicotinic acetylcholine receptors were synthesized on the basis of results from a previous computational study. A predictive 3D-QSAR model was developed using the GRID/GOLPE approach (R2 = 0.94, Q 2 = 0.83, SDEP = 0.34). The SAR was interpreted in terms of contour maps of the PLS coefficients and in terms of a homology model of the α4β2 subtype of the nicotinic acetylcholine receptors. The results reveal that hydrogen bonding from both hydrogens on the protonated amine and from the pyridine nitrogen to a water molecule as well as van der Waals interactions between the substituent bearing the protonated amine and the receptor is of importance for ligand affinity. The combination of 3D-QSAR and homology modeling proved successful for the interpretation of structure-affinity relationships as well as the validation of the individual modeling approaches.